For example, the first‐line PROFILE 1014 phase III trial conducted in ALK‐rearranged NSCLC showed that the rate of grade 3 or 4 pulmonary embolism was 8% for the crizotinib arm and 7% for the chemotherapy arm.28 This evidence concerns the gene ALK and non-small cell lung carcinoma.